<DOC>
	<DOCNO>NCT00431990</DOCNO>
	<brief_summary>The purpose first phase study determine whether , dose , depsipeptide , bortezomib dexamethasone safely administer patient Multiple Myeloma . The second phase study establish whether depsipeptide , bortezomib dexamethasone effective treatment patient multiple myeloma . The study also examine role maintenance therapy depsipeptide .</brief_summary>
	<brief_title>A Phase I/II Trial Romidepsin ( Depsipeptide ) Bortezomib Patients With Relapsed Myeloma</brief_title>
	<detailed_description>Several group explore possible synergistic interaction proteasome HDAC inhibitor malignant hematopoietic cell . Bortezomib HDACIs synergistically induce apoptosis , mitochondrial injury ( via BAX ) , ROS generation oxidative injury human leukemia myeloma cell . In view evidence , propose trial examine clinical effect combine romidepsin bortezomib patient relapsed/refractory MM . However , currently data whether drug safe administer combination dose toxicity may become unacceptable . Trial Design Open label , single centre , single arm , phase I/II dose escalation trial bortezomib-dexamethasone addition romidepsin follow maintenance therapy disease progression . Primary objective : • To determine maximum tolerate dose ( MTD ) romidepsin administer Bortezomib patient relapse multiple myeloma assessment adverse event abnormal laboratory value . Primary endpoint : • Toxicity evaluation four dose level present dose-escalation schedule Secondary objective : • To determine efficacy combination MTD term ( ) overall response , ( ii ) time progression ( iii ) overall survival Secondary endpoint : - Overall response ( OR ) , define best response treatment base M Protein response criterion CR document EMBT standard conjunction soft tissue plasmacytoma response criterion correct serum calcium level . - Time progression ( TTP ) , define time commencement treatment date first evidence progressive disease . - Overall survival ( OS ) , define time commencement treatment date death cause</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 . Patient previously diagnose multiple myeloma base standard criterion treat least one , less 4 line therapy , currently require treatment relapse CR PD . 2 . Patient previously treat bortezomib include study , duration response &gt; 6mths completion therapy . 3 . Patient 's age &gt; 18 yr 4 . Patient , investigator 's opinion , willing able comply protocol requirement . 5 . Patient give voluntary write informed consent . 6 . Female patient childbearing potential male patient female partner childbearing potential , one undergone surgical sterilisation must agree use 2 simultaneous method contraception . For female patient , negative pregnancy test perform within 7 day prior administration study drug . 7 . Patient measurable disease . serum monoclonal protein ( SEP ) &gt; 5 g/L serumfree light chain ( SFLC ) &gt; 100 mg/L urinefree light chain ( UFLC ) &gt; 200 mg/24hr measurable soft tissue ( bone ) plasmacytoma ( STPC ) 8 . Patient Karnofsky performance status ≥80 % . 9 . Patient lifeexpectancy &gt; 3 month . 10 . Patient follow laboratory value within 14 day study drug administration : Platelet count ≥50 × 109/L without transfusion support within 7 day Hemoglobin ≥75 g/L without transfusion support within 7 day Absolute neutrophil count ( ANC ) ≥0.75 × 109/L without use growth factor . Corrected serum calcium &lt; 14 mg/dL ( 3.5 mmol/L ) . Serum potassium ≥ 4.0 mmol/L serum magnesium ≥ 0.85 mmol/L ( electrolyte correct supplementation . See section 9.7 ) . Aspartate transaminase ( AST ) : ≤2.5 × upper limit normal ( ULN ) . Alanine transaminase ( ALT ) : ≤2.5 × ULN . Total bilirubin : ≤1.5 × ULN . Calculated measured creatinine clearance : ≥20 mL/minute . 1 . Prior severe allergic reaction bortezomib ( Velcade ) , romidepsin , boron mannitol 2 . Neuropathy &gt; Grade 3 Neuropathy Grade 2 pain &gt; Grade 1 NCICTCAE criterion ( v3.0 ) . 3 . Patients follow cardiac risk factor exclude study ( per previous NCI trial ) : Congenital long QT syndrome QTc interval &gt; 480 millisecond Patients myocardial infarction within 12 month study entry . Patients active coronary artery disease , e.g . angina define Canadian Class IIIV ( Appendix 3 ) . Patients ECG show evidence cardiac ischemia ( ST depression ≥ 2 mm ) . Patients congestive heart failure meet NYHA Class II IV definition ( Appendix 4 ) and/or ejection fraction &lt; 45 % MUGA scan &lt; 50 % echocardiogram and/or MRI . Patients history sustain VT , VF , Torsade de Pointes , cardiac arrest unless currently address automatic implantable cardioverter defibrillator ( AICD ) . Patients dilate , hypertrophic , restrictive cardiomyopathy prior treatment cause ( doubt , see ejection fraction criterion ) . Patients uncontrolled hypertension , i.e . SBP ≥ 160 mm Hg DBP ≥ 95 mm Hg . Patients cardiac arrhythmia require antiarrhythmic medication beta blocker calcium channel blocker . Patients digitalis discontinue exclude study . Patients Mobitz II second degree heart block , pacemaker . Note : Patients cardiac disease may exclude discretion principal investigator follow consultation cardiologist . 4 . Pregnancy female patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>